Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KIT2014
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kither Launches Phase 1 Study of KIT2014 Inhaled Therapy for Cystic Fibrosis
Details : KIT2014 is a peptide-based therapy designed to inhibit PDE3/4, being investigated for the treatment of CF lung disease in adults.
Brand Name : KIT2014
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 30, 2024
Lead Product(s) : KIT2014
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : KIT2014
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kither Biotech Announces Publication of New Data in Science Translational Medicine
Details : KIT2014, a novel, cell-permeable peptide that works to modulate cAMP levels inside cells, demonstrated a triple mechanism of action in reversing disease pathogenesis: enhancing functionality of CFTR channels and reducing bronchoconstriction and inflamma...
Brand Name : KIT2014
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 31, 2022
Lead Product(s) : KIT2014
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : KIT2014
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Claris Ventures
Deal Size : $18.5 million
Deal Type : Series B Financing
Details : Proceeds will be used to fund the clinical development of Kither’s lead product KIT2014, a novel cell- permeable peptide for the treatment of cystic fibrosis (CF) that works to modulate cyclic adenosine monophosphate (cAMP) levels inside cells.
Brand Name : KIT2014
Molecule Type : Peptide
Upfront Cash : Undisclosed
March 16, 2022
Lead Product(s) : KIT2014
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Claris Ventures
Deal Size : $18.5 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?